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Acute Hepatic Porphyrias: Review and 
Recent Progress
Bruce Wang,1 Sean Rudnick,2 Brent Cengia,2 and Herbert L. Bonkovsky 2
The acute hepatic porphyrias (AHPs) are a group of four inherited diseases of heme biosynthesis that present with 
episodic, acute neurovisceral symptoms. The four types are 5-aminolevulinic acid (ALA) dehydratase deficiency por-
phyria, acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria. Their diagnoses are often 
missed or delayed because the clinical symptoms mimic other more common disorders. Recent results indicate that 
acute intermittent porphyria, the most severe of the more common types of AHP, is more prevalent than previously 
thought, occurring in about 1 in 1600 Caucasians, but with low clinical penetrance (approximately 2%-3%). Here we 
provide an updated review of relevant literature and discuss recent and emerging advances in treatment of these 
disorders. Symptomatic attacks occur primarily in females between 14 and 45 years of age. AHP is diagnosed by 
finding significantly elevated levels of porphyrin precursors ALA and porphobilinogen in urine. Acute attacks 
should be treated promptly with intravenous heme therapy to avoid the development of potentially irreversible neu-
rologic sequelae. All patients should be counseled about avoiding potential triggers for acute attacks and monitored 
regularly for the development of long-term complications. Their first-degree relatives should undergo targeted gene 
testing. Patients who suffer recurrent acute attacks can be particularly challenging to manage. Approximately 20% of 
patients with recurrent symptoms develop chronic and ongoing pain and other symptoms. We discuss newer treat-
ment options in development, including small interfering RNA, to down-regulate ALA synthase-1 and/or wild-type 
messenger RNA of defective genes delivered selectively to hepatocytes for these patients. We expect that the newer 
treatments will diminish and perhaps obviate the need for liver transplantation as treatment of these inborn meta-
bolic disorders. (Hepatology Communications 2019;3:193-206).
Overview of Heme 
Metabolism and the 
Porphyrias
Heme is a primordial molecule that is essential 
to aerobic life on earth. It carries out an astonishing 
and still growing array of functions. It is an essen-
tial cofactor for a myriad of hemoproteins, including 
hemoglobin, myoglobin, cytochromes P-450, mito-
chondrial cytochromes, catalase, peroxidase, and many 
others. In eukaryotes, biosynthesis of heme occurs in 
the mitochondria and cytoplasm, and the formation 
of the heme molecule is a multistep process involv-
ing eight enzymes (Fig. 1). Although most tissues in 
the human body synthesize heme, it is predominantly 
formed by erythroblasts in the bone marrow (75%-
80%) and hepatocytes in the liver (15%-20%). The 
metabolic pathways of heme synthesis are essentially 
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the same in both tissues, although the regulation 
of the rate-limiting enzymes 5-aminolevulinic acid 
synthase 1 (ALAS-1) (hepatic, housekeeping) and 
ALAS-2 (erythroid) is quite different. Porphyrias 
are inborn errors of metabolism that cause deficient 
activity within the eight-step heme synthetic pathway. 
Potential conflict of interest: Dr. Bonkovsky received grants and consults for Alnylam and Mitsubishi Tanabe; he consults for Moderna 
Therapeutics and Recordati; he received grants from Gilead. Dr. Rudnick consults for Alnylam. Dr. Wang consults for Alnylam, Recordati, and 
Mitsubishi Tanabe.
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Fig. 1. Summary of the heme synthetic pathway, highlighting the enzymatic defects associated with the porphyrias. The heme synthetic 
pathway involves eight enzymes, four of which are active in the mitochondria and four of which are active in the cytoplasm. The pathway 
is initiated and completed in the mitochondria. Intermediate steps in the cytoplasm begin with the activity of ALA dehydratase, also 
known as PBG synthase. Open arrows indicate progression through the pathway. Deficiency (indicated by blocked red arrows) in any of 
the eight enzymes involved in the pathway may contribute to the development of acute or chronic hepatic porphyrias or erythropoietic 
porphyrias, as shown in red. Abbreviations: Ac, acetate; CoA, coenzyme A; Copro’gen, coproporphyrinogen; Pr, propionate; proto’gen, 
protoporphyrinogen; Uro’gen, uroporphyrinogen; and Vi, vinyl. (From (43), used with permission of the authors and publisher.)
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These deficiencies can lead to a build-up of heme pre-
cursors, resulting in the clinical manifestations of the 
porphyrias.
The conversion of glycine and succinyl coenzyme 
A to ALA by the mitochondrial enzyme ALAS is the 
rate-limiting step in heme synthesis. In the liver and 
most other tissues in which ALAS-1 is the dominant 
form of the enzyme, heme, the end product of the 
pathway, exerts negative feedback regulation by sev-
eral mechanisms that tightly regulate ALAS-1 activity 
(Fig. 2). Activity of ALAS-1 is also down-regulated by 
high levels of glucose or other metabolizable carbohy-
drates, the so-called glucose effect,(1) acting through 
modulation of peroxisome proliferator–activated 
receptor-gamma coactivator 1 (PGC-1) and other 
transcription factors.(2) ALAS-1 is increased by many 
substances that induce cytochromes P450, which are 
the major users of heme synthesized in hepatocytes, 
as implied by the thick arrow in Fig. 2.
Because of the great demand for heme synthesis 
in developing red blood cells (approximately 80% of 
the total heme synthesized each day), there is a sec-
ond form of ALAS-2 that predominates in such cells. 
It shares considerable homology with ALAS-1, but it 
is a separate gene that is located on the X chromo-
some. Its regulation is quite different from that of its 
housekeeping counterpart. ALAS-2 is not down-reg-
ulated by the end-product heme, but rather is under 
the regulation of erythroid transcriptions factors, such 
as GATA binding factor-1 (GATA-1), also known as 
erythroid transcription factor, and the iron regulatory 
element–iron regulatory protein system. Thus, when 
there is deficiency of iron, activity of erythroid ALAS-2 
is restricted, with the eventual effect of restricting 
Fig. 2. Key role of heme in the regulation of hepatic ALAS-1 and heme metabolism. The figure shows the central role of the regulatory 
heme pool in regulating the activity of hepatic ALAS-1 at the level of mRNA stability and uptake of the pre-enzyme into mitochondria. 
Heme also down-regulates transcription of ALAS-1 and increases the rate of breakdown of the mature enzyme in mitochondria.(3) 
Abbreviation: CoA, coenzyme A.
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production of excess protoporphyrin, which is toxic 
to cells and would otherwise pile up in the absence 
of sufficient iron to fuel its conversion to heme. It is 
worthy of note that gain-of-function mutations of 
ALAS-2 are the cause of the often-severe cutaneous 
porphyria known as X-linked protoporphyria (XLP), 
the phenotype of which closely resembles that of 
erythropoietic protoporphyria (EPP).
In both hepatocytes and erythroblasts, there are 
six additional steps required to convert ALA to pro-
toporphyrin IX (Fig. 1). In the final step, ferroche-
latase inserts ferrous iron into the protoporphyrin 
macrocycle to form heme. Enzyme deficiencies in 
any of the eight-step heme synthetic pathway can 
cause clinically apparent porphyria.(3) In acute por-
phyrias, the respective enzyme deficiencies predispose 
patients to a variety of triggering factors, especially 
drugs and female sex hormones, which induce the 
accumulation of the neurotoxin ALA and porpho-
bilinogen (PBG).
The eight porphyrias are generally categorized 
in one of two ways: according to the main site of 
overproduction of heme precursors (hepatic or 
erythropoietic) or according to the cardinal clinical 
features (acute or cutaneous) (Table 1). The AHPs, 
which are the focus of this review, are a group of four 
inherited disorders: acute intermittent porphyria 
(AIP), hereditary coproporphyria (HCP), variegate 
porphyria (VP), and ALA dehydratase deficient 
porphyria (ALADP). AIP, HCP, and VP arise from 
autosomal dominant mutations of the genes that 
control normal hepatic heme biosynthesis, resulting 
in approximately 50% deficiencies of the enzymes 
hydroxymethylbilane synthase (HMBS, also known 
as PBG deaminase), coproporphyrinogen oxidase 
(CPOX), and protoporphyrinogen oxidase (PPOX), 
respectively. These enzyme deficiencies, in combina-
tion with other environmental factors (nutritional, 
hormonal, or other genetic factors), can lead to a 
critical deficiency in heme within a small but critical 
“regulatory pool” within hepatocytes (Fig. 2.) In the 
United States and most other countries of the world, 
AIP is the most common and most symptomatic of 
the three autosomal dominant conditions, occurring 
taBle 1. main sCHemes oF ClassiFiCation anD seleCteD aspeCts oF tHe poRpHyRias
Acute Hepatic Porphyrias Chronic Hepatic Porphyrias Erythropoietic Porphyrias
Types of porphyria 1. ADP 1. PCT 1. CEP
2. AIP 2. HEP 2. EPP
3. HCP 3. XLP
4. VP
Gender frequency Female > male (~4 > 1) Male > female Female = male
Main site of overproduction 
of heme precursors
Liver Liver Erythroblasts
Inheritance AIP, HCP, VP (autosomal dominant); 
ALADP (autosomal recessive)
1. Usually acquired 1. CEP
2. Autosomal recessive or codominant 2. EPP (autosomal recessive)
3. XLP-X-linked
Key clinical features Neurovisceral symptoms 
(photocutaneous disease in HCP, 
VP)
Cutaneous lesions on sun-exposed 
areas, especially after minor 
mechanical trauma (painless blisters, 
skin fragility, sclerodermatous 
changes, cheeks and temples, 
hypertrichosis)
1. CEP (cutaneous lesions on 
sun-exposed areas [painless blisters, 
skin fragility, sclerodermatous 
changes, hypertrichosis])
2. EPP
3. XLP (acute burning, pain, pruritus, 
swelling after sun exposure)
Key biochemical findings in 
active disease
1. ALADP (increased urinary ALA, 
CP 3)
Increased urinary uroporphyrins and 
heptacarboxyl-porphyrins; increased 
stool isocoproporphyrins
1. CEP (increased urinary uroporphyrin 
1, CP 1)
2. AIP 2. EPP
3. HCP 3. XLP (urine is normal unless 
hepatopathy has developed); 
increased PP in plasma and RBCs
4. VP (increased urinary ALA, PBG, 
uroporphyrin 1, CP 3) HCP 
(increased stool CP)
VP (increased stool PP)
Abbreviations: CP, coproporphyrin; PP, protoporphyrin; and RBC, red blood count.
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in 5 to 10 per 100,000 patients, and the most clin-
ically severe. This is likely due primarily to the fact 
that, even under normal circumstances, activity of 
hepatic HMBS is relatively low and only slightly 
above that of ALAS-1. Therefore, a 50% decrease in 
activity of HMBS is more likely to critically limit 
hepatic heme production and lead to uncontrolled 
up-regulation of hepatic ALAS-1, which is the sine 
qua non of acute porphyric attacks.(3) Because of 
a strong founder effect among Afrikaners, VP is 
more common in South Africa than other locations. 
Although VP and HCP can give rise to neurologic 
symptoms similar to AIP, cutaneous manifestations 
may rarely also occur in HCP and often predom-
inate in VP. ALA dehydratase deficiency is a rare 
autosomal recessive disorder in which enzymatic 
activity is less than 3% of normal (compared with 
asymptomatic carriers who have 50% of normal 
enzyme activity).
The cutaneous porphyrias include congenital 
erythropoietic porphyria (CEP), EPP, XLP, hepa-
toerythropoietic porphyria (HEP), and porphyria 
cutanea tarda (PCT). The cutaneous porphyrias usu-
ally exhibit no neurologic symptoms. A rare excep-
tion is EPP complicated by serious hepatopathy, in 
which case a few patients have developed neurolog-
ical deficits, especially after liver transplantation.(4) 
In these diseases, excess porphyrins and porphyrin-
ogens are deposited in the upper dermal capillary 
walls. These compounds are potent photoreactants 
that cause tissue damage, manifesting as cutaneous 
vesicles and bullae and increased skin fragility (CEP, 
HEP, PCT) or as acute pain, burning, and swelling 
(EPP, XLP) in skin exposed to sunlight. Over time, 
in CEP, HEP and PCT scarring, pigment changes, 
infection, and excessive hair growth (hypertrichosis) 
can occur.
Major Clinical Features of 
the AHPs
We first present a clinical vignette of a typical 
patient with AIP to emphasize the key aspects of 
presentation and diagnosis. A 28-year-old woman 
carrying a diagnosis of irritable bowel syndrome, 
constipation predominant, for 10 years (after pre-
vious imaging and endoscopic evaluation by a 
gastroenterologist) presented to the emergency 
department (ED) for the fourth time in 12 months 
for evaluation of severe abdominal pain, constipa-
tion, nausea, vomiting, and weakness. Surgical his-
tory is notable for an appendectomy, carried out at 
age 20, after an earlier episode of severe abdominal 
pain, despite a lack of computed tomography (CT) 
findings to suggest acute appendicitis. The appendix 
was said to have shown “mild chronic appendicitis.” 
The patient underwent a cholecystectomy 2 years 
ago for similar symptoms and a diagnosis of acalcu-
lous “chronic cholecystitis.”
Since the time of cholecystectomy, she has con-
tinued to have intermittent severe abdominal pain 
requiring repeated ED visits. Opioid pain medica-
tions provided minimal relief. On presentation, vital 
signs were notable for tachycardia (heart rate = 112/
minute), systemic arterial hypertension (175/100 
mm Hg), and normal oxygen saturation and respi-
ratory rate. Physical exam was otherwise unremark-
able, including a benign abdominal exam, despite the 
patient complaining loudly of severe stabbing lower 
abdominal pain. The CT of the abdomen/pelvis was 
unremarkable, noting only the previous appendec-
tomy and cholecystectomy with expected mild com-
mon bile duct dilation and much stool in the colon. 
(The patient described chronic constipation with 
usual bowel movements only once or twice per week.) 
Laboratory evaluation was notable for minor eleva-
tions of serum aminotransferases (aspartate amino-
transferase = 42 U/L; alanine aminotransferase = 48 
U/L), hyponatremia (Na+ = 128 mEq/L), and hypo-
magnesemia (Mg++ = 1 .1 mg/dL). Urinalysis showed 
dark amber to brownish urine that is negative for 
blood or bilirubin. The urinalysis was otherwise unre-
markable. A test for pregnancy was negative. An astute 
medical resident considered the diagnosis of an AHP, 
based on the constellation of symptoms and signs, 
and obtained a random urine sample for ALA, PBG, 
and creatinine. This was sent to a reference laboratory. 
The patient was treated with intravenous fluids that 
included 5% dextrose and 0.154 M NaCl and with 
promethazine, ondansetron, and narcotic analgesics, 
with partial gradual improvement over the ensuing 
24 hours. She was discharged from the ED. After 5 
days, the results of the spot urine test was returned 
(ALA = 38 mg/g creatinine [ref 0-7]; PBG = 85 mg/g 
creatinine [ref 0-4]), establishing a diagnosis of AHP. 
There was no history of cutaneous lesions. Genetic 
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testing for mutations in all four of the genes involved 
in the AHPs revealed that the patient had a single 
missense mutation in the HMBS gene (p. R167Q), 
which is known to be associated with AIP. Genetic 
testing of all first-degree relatives was recommended 
(Table 2).
As already described, the more common AHPs are 
inherited in an autosomal dominant pattern.(3,5) The 
most common and generally most severe type is AIP. 
Although previously thought to be quite rare, more 
recent population-based data indicate that poten-
tial disease-causing mutations in HMBS occur in 
approximately 1 in 1700 Europeans (Nordmann et 
al., approximately 1996). Thus, newer evidence indi-
cates that disease penetrance is low (estimated to be 
1%-2%), with more than 90% of heterozygotes with 
disease-causing mutations remaining asymptomatic 
for most or all of their lives, highlighting the facts that 
other factors are important in pathogenesis and that 
patients with severe disease represent only a small pro-
portion of those carrying disease-causing mutations.(6)
The preceding vignette describes a typical case his-
tory of AHP. Attacks are characterized by the devel-
opment of acute neurovisceral pain. Attacks occur 
most frequently in young women (83%) compared 
with males (17%).(7) Abdominal pain with nausea, 
vomiting, and accompanied weakness are the most 
common presenting symptoms. Pain tends to be 
localized to the lower abdomen and is often described 
as colicky in nature. It generally lasts hours to days 
and is poorly responsive to narcotic pain medications. 
Neurologic manifestations such as weakness and 
altered affect may be subtle, requiring a high index of 
suspicion. Signs often existing at presentation include 
tachycardia, hypertension, and dark-colored urine, as 
in the patient described. Seizures occur during acute 
attacks in approximately 20% of patients, and if they 
are treated with hydantoins, barbiturates or valproic 
acid, the severity of the attacks is often amplified 
many-fold.
The clinical history usually reveals recurrent symp-
toms with repeated, frequently nondiagnostic medical 
evaluations. The nonspecific symptoms may result in 
inaccurate diagnoses and unnecessary and ineffective 
surgical interventions (e.g., appendectomy, cholecys-
tectomy, hysterectomy), as in the case described. The 
nonspecific signs/symptoms, coupled with nondiag-
nostic evaluations, result in mean delay in diagnosis of 
approximately 15 years.(7)
The neurological manifestations of acute porphyr-
ias deserve specific attention, as they can be some of 
the most life threatening. Paresis/weakness generally 
begins proximally. This can progress to respiratory 
paralysis in some cases.(8) Convulsions/seizures are 
not uncommonly seen (10%-20%), and careful atten-
tion to choice of anti-epileptic medication for treat-
ment is required (see “Management of Acute Attacks” 
section).
Common laboratory abnormalities observed in the 
setting of acute attacks of porphyria include hypo-
natremia (most common). In some circumstances, 
hyponatremia may be severe and contribute to the 
development of seizures. Hypomagnesemia is also 
common. Mild aminotransferase elevations can also 
be observed. During acute attacks, the passage of 
reddish-brown urine may be noted. If left exposed to 
air and light at room temperature, urine may darken 
further, which should prompt consideration of the 
diagnosis.
Keys to Diagnosis and 
Differential Diagnosis
Contrary to urban legend, it is not difficult to 
establish or rule out a diagnosis of AHP, provided 
that physicians or other providers think of the diag-
nosis and perform the appropriate diagnostic testing. 
taBle 2. Common symptoms anD signs oF 
aHps in suBJeCts WitH CliniCally aCtiVe 
Disease
Symptoms Signs
Pain Systemic arterial hypertension (43%)
Abdominal (74%) Chronic kidney disease (29%)
Back (56%) Palpitations/tachycardia (19%)
Chest (58%) Hyponatremia (20%)
Nausea/vomiting (73%) Fever (18%)
Weakness (63%) Hypomagnesemia (11%)
Constipation (60%)
Anxiety/depression (55%)
Diarrhea (29%)
Sun sensitivity (20%)
Chronic fatigue (11%)
Seizures (9%)
Note: Adapted from (7).
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As in the described clinical vignette, AHP should be 
considered in any patient, but especially in women 
in their child-bearing years who present with recur-
rent, severe episodes of abdominal pain. The pain may 
occur elsewhere as well, including the back, extrem-
ities or chest, but is first and foremost in the abdo-
men. The first test of choice for diagnosis is a single 
random urine screening for ALA, PBG, and creati-
nine—not porphyrins. In our experience, the most 
frequent errors lie in (1) not considering the diagno-
sis in a timely fashion, leading to the average 15-year 
delay in the United States from time of first symp-
toms to eventual correct diagnosis,(7) and (2) ordering 
a random urine screening for porphyrins rather than 
for ALA and PBG. As described subsequently (in the 
“Secondary Porphyrinurias” section), many patients 
without any form of porphyria will show mild to 
moderate increases in urinary porphyrins, especially 
in coproporphyrins I and III. When these are found 
in patients with diverse symptoms, including abdom-
inal pain, joint pain, muscle pain, fibromyalgia, anx-
iety and chronic fatigue syndrome, such patients, 
unfortunately, are labeled as having porphyria when 
they do not. Too often, this leads to the patients and 
their physicians ascribing a plethora of symptoms to 
an inaccurate diagnosis. Unfortunately, some of these 
patients have had central venous ports inserted and 
have been treated with recurrent infusions of intra-
venous heme, sometimes with disastrous results, such 
as recurrent infections and/or thrombosis of ports and 
central veins, thrombophlebitis, sepsis, and develop-
ment of secondary iron overload (heme is 9% iron by 
weight).
Another misconception is that the pains and other 
features of AHP are transient and fleeting; they are 
not. Rather, they occur with a prodrome that is typical 
for the patient, with gradual crescendo. The pain typ-
ically lasts for several days and only gradually abates. 
Many patients try to treat their recurrent, often 
monthly attacks during the luteal phase of their men-
strual cycles (when progesterone levels are at maximal) 
with narcotics or other analgesics and with increases 
in glucose intake. They try to avoid having to present 
to the ED or urgent care, because, too often, prompt 
and appropriate specific treatment with intravenous 
dextrose and heme and adequate narcotic analgesics 
is delayed or not provided at all. Such unfortunate 
patients are too often labeled as “drug seeking” or 
malingering. The latter has become much worse since 
the advent of the opioid overdose epidemic that has 
swept the United States, and shows no sign of abating.
As described in the clinical vignette, the key to 
diagnosis is measurement of ALA, PBG, and creat-
inine in a single spot urine test collected during or 
within a few days of an acute attack. Levels of ALA 
and/or PBG, expressed as per gram or per millimole 
creatinine in the urine, that are greater than four times 
the upper limit of normal establish the diagnosis of 
AHP. Most such patients will prove to have AIP, 
which is the most common and most severe form of 
AHP throughout the world, with the exception of 
South Africa, where, due to a founder effect, there are 
thousands of persons with the genetic defect in PPOX 
associated with VP. After an acute attack of AIP, uri-
nary ALA and PBG remain elevated for many months 
to years.(9) Thus, in bona fide AIP, collection of urine 
does not need to take place during the peak of clinical 
symptoms; unless the patient has been treated with a 
4-day to 5-day course of intravenous heme, the urine 
can be collected days or weeks after the acute attack. 
This is less so in HCP or VP, in which levels of uri-
nary ALA and PBG more often fall quickly after an 
acute attack. In these disorders, however, stool porphy-
rins are usually markedly elevated chronically and for 
years, and/or the fluorescence peak emission of serum 
points to the correct diagnosis (see subsequently).
The specific type of acute porphyria that is pres-
ent now is usually established by genetic testing, with 
sequencing of the four genes that are defective in the 
acute porphyrias (i.e., ALAD, HMBS, CPOX, and 
PPOX) (Fig. 1). Such testing is available commer-
cially at several labs, including Invitae (San Francisco, 
CA), Mayo Medical Labs (Rochester, MN), and 
Department of Genetics, Icahn School of Medicine 
(New York, NY). Another test of considerable use 
for diagnosis of VP is fluorescence of diluted sera 
at physiologic pH. The sera from subjects with VP, 
especially with biochemical activity, have a unique 
porphyrin-peptide in plasma that has peak fluores-
cence at approximately 626 nm, following excitation 
by light of 410 nm (the Soret band). In contrast, the 
sera of subjects with biochemically active AIP, CEP, 
HCP, HEP, or PCT have emission peaks at approx-
imately 619 nm to 620 nm, whereas those with EPP 
or XLP have peak emission peaks of protoporphyrin 
at approximately 634 nm.(3)
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Management of Acute 
Attacks
Initial management includes discontinuation of any 
potential precipitants and management of symptoms. 
A thorough history to identify possible precipitating 
factors, specifically medications/chemicals, should be 
performed. If culprit agents are identified, these should 
be discontinued immediately. Common precipitants 
include excess alcohol intake, estrogen/progesterone, 
barbiturates, sulfonamides, and, more generally, any 
known inducers or suicide substrates of hepatic cyto-
chromes (Table 3). Consultation with the American 
Porphyria Foundation website (www.porphyriafoun-
dation.com/drug-database) and a newer mobile app 
(available at porphyriadrugs.com) is advised, as mul-
tiple medications commonly used in symptom man-
agement may have unanticipated deleterious effects. 
Other drug databases available on the Internet include 
one developed especially for European countries 
(www/drugs-porphyria.org), a safe drug list produced 
jointly by the UK Porphyrias Medicines Information 
Service and the Cardiff Porphyria Service (www.
wmic.wales.nhs.uk). These lists do not always agree, 
but, in general, we recommend caution in the use of 
drugs and herbals and dietary supplements for all per-
sons, especially those with AHP.
Initial treatment in patients with confirmed acute 
porphyria without evidence of infection includes high 
carbohydrate intake (10% dextrose in 0.45% saline). 
Narcotic analgesics and anti-emetics (chlorpromazine 
or promethazine and ondansetron, which have been 
found to be “safe” drugs in AHPs) are preferred.
At the pathophysiologic level, the goal of treatment 
in acute attacks is to reduce the activity of hepatic 
ALAS-1. Carbohydrate/glucose administration works 
to down-regulate ALAS-1, thus resulting in decreased 
production of ALA and PBG, and at least 300 g of 
glucose or similar should be given daily. However, the 
most effective therapy in decreasing ALAS-1 activity is 
the administration of intravenous heme (in the United 
States, Panhematin; in Europe, Normosang [Recordati 
Rare Chemicals]), which results in a decrease in urine 
and plasma ALA and PBG after two to three infu-
sions,(3,10) with improvement in symptoms generally 
observed within 4 days.(11)
Given its instability in aqueous solution, it is recom-
mended that Panhematin be reconstituted in human 
albumin and given at a dose of 3-4 mg/kg/day.(12,13) 
There is potential risk for painful phlebitis when intra-
venous heme is administered into peripheral veins; 
thus, administration into a high-flow, central vein is 
recommended.(12) This risk is likely decreased when 
heme is administered as the heme-albumin complex, 
which not only stabilizes the heme but also appears to 
diminish its toxicity to vascular endothelium. Other 
potential adverse effects of intravenous heme include 
transient thrombocytopenia and prolongation of pro-
thrombin time (without resultant bleeding diathesis), 
hepatic iron overload (with repeated, chronic adminis-
tration), and development of tachyphylaxis.(14,15)
Monitoring for and treatment of expected elec-
trolyte abnormalities, including hyponatremia and 
hypomagnesemia, is recommended. In addition to 
electrolyte replacement, if associated seizures are 
present, gabapentin and vigabatrin are the preferred 
anticonvulsant agents. Of note, commonly used anti-
convulsants, including barbiturates, phenytoin, val-
proic acid and carbamazepine, should be avoided in 
patients with acute porphyria, as they may result in 
severe exacerbation of the attack and rapid devel-
opment of profound weakness and acute respiratory 
compromise that requires mechanical ventilation.
The incapacitating pain associated with acute 
attacks nearly universally requires use of parenteral 
narcotic analgesics. If appropriate therapies (intrave-
nous glucose and heme, safe analgesics) are admin-
istered without delay, improvement in pain should 
result within 3 to 5 days. Tachycardia and systemic 
arterial hypertension in acute attacks result from 
sympathetic hyperactivity. The preferred agents 
include beta blockers, angiotensin-converting enzyme 
taBle 3. Common pReCipitants oF aCute 
attaCKs
Drugs/Chemicals Other Causes
Excess alcohol Rapid weight loss
Anticonvulsants Crash dieting, starvation
Barbiturates Bariatric surgery
Carbamazepine Acute illness/infections
Phenytoin Stress/exhaustion
Primidone Emotional/physical
Valproic acid Surgery/anesthesia
Oral contraceptives Luteal phase of menstrual cycle
Sulfonamides Pregnancy
Cytochrome P450 inducers Postpartum period
Suicide substrates of Cyp P450s
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inhibitors, and calcium channel blockers (diltiazem is 
preferred over nifedipine, which is porphyrogenic in 
model systems).(16)
Some patients have predictable triggers for acute 
attacks that should be avoided and minimized as 
much as possible. There are multiple possible incit-
ing factors that physicians should address (Table 3). 
Medications including but not limited to estrogens, 
progestogens, barbiturates, sulfonamides, and other 
inducers of cytochromes P450 and ALAS-1 should be 
avoided, and websites with recommendations based on 
existing evidence should be consulted before starting 
any new medications. Patients should avoid smoking, 
including marijuana, and avoid heavy alcohol intake, 
as each can induce cytochromes P450, and alcohol is 
known to induce hepatic ALAS-1.(17) We recommend 
in general that men should adhere to no more than 
two, and women to no more than one, drink per day.
Sources of physical, psychological, and emotional 
stress should be avoided as much as possible. Infection 
or other illness that can cause metabolic stress can 
incite an attack; thus, prompt treatment of intercurrent 
infections or other illnesses with safe antibiotics and 
hydration is essential. All appropriate vaccinations to 
prevent infections that may trigger an attack should be 
administered. Consultation with a dietitian should be 
considered to promote and maintain a well-balanced 
diet somewhat high in carbohydrates (60%-70% of total 
calories). Extreme dieting, severe caloric restriction, and 
starvation should be avoided. First acute attacks have 
been reported following weight loss surgery.(18)
Some women suffer monthly recurrent attacks 
during the luteal phase of their menstrual cycles and 
can have symptomatic improvement with a gonado-
tropin-releasing hormone analogue (leuprolide or his-
trelin) to suppress ovulation. Others report decreased 
symptoms when they take low-dose oral contracep-
tives. Most women with AIP tolerate pregnancy well 
despite increased serum-circulating progesterone. 
Some women have more frequent attacks while preg-
nant; such attacks are treated in the same manner as for 
nonpregnant women, and experience has shown intra-
venous heme to be safe and effective during pregnancy.
In VP, dietary supplementation with vitamins C 
and E may mitigate oxidative damage in plasma and 
neutrophils.(19) In patients with cutaneous manifes-
tations, skin trauma should be minimized as much 
as possible, as excessive mechanical manipulation 
can increase the damaging effects of photoreactive 
compounds. Usual sunscreens are of little help in the 
cutaneous porphyrias, as they do not block light in 
the Soret region (about 400 nm-420 nm). Opaque 
sunscreens with zinc or titanium oxide paste are of 
more benefit, although they leave white pigment on 
the skin. Special filters, such as CLS-200-X or TA-81 
(Madico, Woburn, MA), can be used to protect against 
strong indoor lighting (particularly fluorescent lights 
or lights used in operating rooms).
Hematin infusions inhibit the stimulus for heme 
production, thereby diminishing or eliminating man-
ifestations of the disease. A minority of patients 
require prophylactic intravenous heme, typically once 
or twice per week. In select patients, this may mark-
edly improve quality of life and decrease total health 
care costs.(20)
Natural History: 
Recommendations for  
Long-Term Follow-up
CHRoniC seQuelae
Although most symptomatic patients with AHP 
have complete resolution of their symptoms between 
attacks, those with multiple recurrent attacks may 
develop chronic pain. The pathogenesis of chronic 
pain in these patients is poorly understood, but nerve 
conduction and electromyogram studies often reveal 
chronic neuropathy, typically an axonal motor poly-
neuropathy.(8,21) Referral to a neurologist is recom-
mended for any patient with residual neurologic 
deficits. These chronic symptoms may not respond to 
administration of heme, and referral to a pain man-
agement specialist may be helpful for management 
of chronic neuropathic pain. Patients with AHP with 
persistent chronic pain symptoms can develop severe 
depression and anxiety, which are associated with an 
increased risk for suicide, and may require psychiatric 
monitoring and care.(22)
Of patients with AHP, 13% have increased 
serum aminotransferases during an acute attack.(23) 
Asymptomatic patients may also show increased 
aminotransferases, although to a lesser degree.(24) 
Persistent elevations in serum aminotransferases are 
common in patients who have recurrent attacks. The 
risk for developing cirrhosis is greater in patients with 
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AHP than the general population. Regardless of cir-
rhosis status, patients with AHP have an increased 
risk for hepatocellular carcinoma (HCC).(25,26) HCC 
develops more commonly in symptomatic patients 
over 60 years of age.
Patients with AHP are also at increased risk 
for developing chronic renal disease.(27,28) The 
renal pathology is typically chronic tubulo-inter-
stitial nephropathy or focal cortical atrophy.(28) 
Asymptomatic patients without elevated porphyrin 
precursors and porphyrins are not at risk of chronic 
renal disease.(29) Although systemic arterial hyper-
tension usually resolves after resolution of an acute 
attack, some patients may develop chronic hyperten-
sion, which may be a cause of chronic renal damage. 
Referral to a nephrologist is recommended if hyper-
tension is not controlled by first-line treatment or 
when renal dysfunction is first recognized. A common 
variant of peptide transporter 2, a transporter for ALA 
in the kidney and brain, may predispose patients with 
AHP to develop chronic renal disease.(30) A number 
of patients with AHP have required dialysis or renal 
transplantation.
long-teRm management
Symptomatic patients with AHP should be fol-
lowed at least annually and more frequently if they 
are receiving prophylactic treatment or continue 
to have acute attacks. Asymptomatic patients who 
have elevated porphyrin precursor levels should also 
be followed annually. Liver function tests should be 
checked in all patients at baseline. An initial abdom-
inal ultrasound and Fibroscan to screen for the pres-
ence of advanced liver disease should be performed. 
Patients found to have elevated liver enzymes or 
abnormal liver imaging should be evaluated for con-
comitant liver disease. Those with evidence of chronic 
liver injury should have cirrhosis and HCC screen-
ing starting at age 50 with Fibroscan, ultrasound, and 
serum alpha-fetoprotein annually. For those without 
evidence of chronic liver injury, annual screening is 
recommended starting at age 60.
Due to the high prevalence of chronic kidney 
disease, serum creatinine and estimated glomeru-
lar filtration rate should be monitored annually for 
all symptomatic patients. Hypertension can be diffi-
cult to manage, particularly during acute attacks, and 
blood pressure should be actively managed to prevent 
further decline in renal function. Hyponatremia may 
be chronic in some patients and may require careful 
Na+ replacement therapy and/or limitation of free 
water intake. Although the hyponatremia has often 
been ascribed to the syndrome of inappropriate antid-
iuretic hormone (ADH) secretion, when blood vol-
umes were measured in patients with AIP, they were 
often found to be decreased.(31) Thus, they do not 
truly fulfill the diagnostic criteria for the syndrome of 
inappropriate secretion of ADH. More detailed rec-
ommendations regarding long-term management and 
follow-up of subjects with AHP have been published 
recently by the Porphyrias Consortium.(32)
pRognosis
Data scarcely regard the prognosis of individuals 
with AHP due to the rarity of the conditions. Earlier 
studies showed increased mortality in patients with 
severe clinical manifestations.(22) However, since the 
introduction of heme therapy, mortality has improved 
in these patients. Overall, patients can have a good 
prognosis, especially if their disease remains latent. 
When the diagnosis is made in a timely fashion, 
acute attacks are managed rapidly and future attacks 
prevented.
Patients with severe, intractable, and disabling 
attacks that are refractory to heme can be considered 
for orthotopic liver transplantation (OLT), which 
has been shown to be curative for these patients.(33) 
However, due to the high morbidity and mortality 
associated with OLT, it is considered a treatment of 
last resort. Moreover, it has not been successful in 
patients with advanced neuropathy. Effects are also 
less clear for patients with ADP or severe homozy-
gous deficiency of HMBS.(34) Some patients with 
both intractable recurrent attacks and end-stage 
renal disease have benefitted from combined liver 
and kidney transplantation.(35)
Secondary Porphyrinurias: 
Common Causes of 
Misdiagnosis
In the experience of the senior author, now 
stretching back 50 years, the most common cause 
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of overdiagnosis (and erroneous diagnosis) of AHP 
is related to mild or moderate increases in urinary 
porphyrins, usually primarily coproporphyrins I and 
III. This occurs because providers fail to order the 
correct urinary test (i.e., ALA, PBG, and creati-
nine) and instead order only spot or 24-hour urine 
tests for porphyrins. There are many reasons for 
levels of such porphyrins to be mildly or moder-
ately elevated, and most of them are not porphyrias. 
The most common are excess alcohol and/or fatty 
liver disease. However, any condition that produces 
mild cholestasis or adversely affects the function of 
organic ion transport activity from hepatocytes into 
bile canaliculi may lead to a shift of coproporphyrin 
excretion from the bile and stool to the urine. In 
addition, many drugs, especially inducers of hepatic 
cytochromes P450, lead to mild induction of ALAS-1 
and to a mild increase in hepatic coproporphyrin 
production and/or to competitive inhibition of the 
organic anion transporters. In fact, elevations in uri-
nary coproporphyrin levels have been proposed as 
biomarkers for such drug effects.(36) Other causes 
of mild porphyrinuria without porphyria include 
a variety of anemias and dyserythropoietic states, 
heavy metal exposures, diabetes mellitus, chronic 
heart diseases, and many others.(3,37,38) Regrettably, 
many patients with increases in urinary porphyrins 
have been mislabeled as having porphyria, when, 
in fact, they do not. Such overdiagnosis can lead to 
inappropriate, expensive, and potentially dangerous 
overtreatment with intravenous heme and other 
therapies. The importance of early and correct diag-
nosis—and of ruling out a diagnosis of AHP—can-
not be overemphasized.
Emerging New Therapies 
for AHP
There has been no new effective therapies for AHP 
since the demonstration of the efficacy of intrave-
nous heme(10) and the development of Panhematin 
(hydroxyheme) and Normosang (heme arginate). 
Intravenous heme has withstood the test of time, 
and, with high glucose/carbohydrate intake, it con-
tinues to be the treatment of choice for acute por-
phyric attacks. Unfortunately, it has potential adverse 
effects, and there are patients for whom, with repeated 
use, tachyphylaxis develops (diminishing benefi-
cial and increasing adverse effects). Thus, additional 
approaches to therapy, short of liver transplantation, 
are needed. Another approach for the down-regulation 
of ALAS-1 is to introduce a small inhibitory RNA 
(siRNA) specifically into hepatocytes. In general, the 
use of siRNAs as therapeutic agents is an exciting 
new field in therapeutics. A complementary approach 
may be to selectively introduce wild-type messenger 
RNA (mRNA) for deficient genes and proteins into 
hepatocytes, to increase wild-type protein levels suffi-
ciently to overcome critical deficiencies in metabolic 
pathways. Both of these approaches are being pursued 
for therapy of AHPs.
Thus, because uncontrolled up-regulation of ALAS-1 
in hepatocytes is the sine qua non for acute por-
phyric attacks, a novel treatment might be to intro-
duce siRNA against ALAS-1, specifically targeted 
to hepatocytes, by binding to asialoglycoproteins, 
which are taken up preferentially by the asialoglyco-
protein receptors of hepatocytes. The specific drug 
that has shown good effect in preclinical studies in 
murine models(39) and in phase I and phase IIa clin-
ical trials in humans is Givosiran (Alnylam Pharma, 
Cambridge, MA) (Fig. 3). Givosiran, which is given 
once every month or two by subcutaneous injection, 
has been selectively taken up by hepatocytes and has 
led to marked and sustained decrements in urinary 
ALA and PBG in subjects with AHP and chronic 
high secretion of ALA and PBG, and to significant 
and clinically meaningful decreases in frequency and 
severity of acute attacks, hospitalizations, and intrave-
nous heme therapy.(40) Givosiran has had a favorable 
safety profile overall in these initial studies, which 
has led to the design and implementation of a piv-
otal phase III, multicenter, placebo-controlled, dou-
ble-blind randomized prospective clinical trial that is 
currently in progress. This trial involves 6 months of 
treatment with Givosiran or matching placebo, fol-
lowed by 18 months of open-label therapy. It is being 
performed at centers throughout the world, and initial 
interim results will be available in the spring of 2019.
Another recent approach that was tried in Spain 
was to administer recombinant human wild-type 
HMBS DNA packaged in adeno-associated virus 8. 
The idea was that enough of the wild-type DNA 
would get into hepatocytes and increase HMBS 
activity sufficient to decrease the overproduction of 
ALA and PBG and ameliorate symptoms of AIP. 
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Unfortunately, this trial did not show any efficacy.(41) 
Perhaps more promising is to introduce mRNA for 
HMBS selectively into hepatocytes, an approach 
being pursued by Moderna Therapeutics (Cambridge, 
MA). They have encouraging positive biochemical 
and clinical effects in murine models of AIP,(42) and 
phase I and IIa studies in human subjects are antici-
pated to start within the next year.
In summary, the AHPs are more common than 
previously thought, although the clinical disease is 
rare. The keys to diagnosis are to think of the possi-
bility of AHP early in the evaluation of persons, espe-
cially women between the ages of 14 and 45 years, 
and to obtain a random urine for measurement of 
ALA, PBG, and creatinine. Any with elevations of 
ALA and/or PBG above 4-fold the upper limit of 
normal should be assumed to have an AHP, treated 
appropriately, and undergo genetic testing to pinpoint 
the affected gene and locus. First-degree relatives of 
affected persons should undergo targeted genetic test-
ing for the same mutation. Intravenous heme remains 
the time-honored treatment of first choice, but in the 
future, there is the promise of siRNA and/or mRNA 
of defective genes delivered selectively to hepatocytes. 
We expect that the newer treatments will diminish 
and perhaps obviate the need for liver transplantation 
as treatment of these inborn metabolic disorders.
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